In AD patients, we observed significantly lower concentrations of soluble Aβ42 (Fig. 2.F; P = .0037), and higher concentrations of total-tau (Fig. 2.G, P = .005) than in CN (APOE carriers and non-carriers pooled together). This evidence concerns the gene MAPT and Alzheimer disease.